Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.98-9.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MRVI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Secure $150 million credit facility by 2026-Q2 | A supporting condition in Maravai LifeSciences Holdings, Inc.'s published investment case. The stated target is $150 million credit secured. | Intact | Failure to maintain or renew credit facility by 2026-Q3 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
MRVI is an early-stage profitability story with exposure to a healthcare sector tailwind. Its thesis state is intact, but the evidence is mixed because the company remains loss-making and the risk level is elevated.
The valuation evidence points to MRVI as cheap versus peers, while also showing a 57% premium versus peers, so the comparison is not clear-cut. The expectations gap is negative, but model confidence is low; the evidence does not support a firm conclusion about what the market already assumes.
In the near term, recent results show revenue growth and a shift to positive adjusted EBITDA in the reported quarters, though profitability progress is mixed. Management has reduced long-term debt and extended its maturity, while the recent termination of a material agreement adds uncertainty. Guidance cuts after a recent increase and weakening jobs data are key near-term risks.
Over the next one to three years, the thesis hinges on sustaining revenue growth and turning improved adjusted EBITDA into durable profitability. A guidance reversal or weaker economic conditions would challenge confidence, while continued strong results and guidance from healthcare bellwethers could support the sector backdrop.
MRVI’s multi-year view remains intact, but it depends on continued execution toward profitable growth amid elevated risk and mixed valuation signals. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Maravai LifeSciences Holdings, Inc.'s published investment case. The stated target is Operating loss near -$2.16 million. |
| Improving |
| Operating loss worsens beyond -$10 million in next quarters |
Operating income: $-15.089M FY2026-Q2; GAAP. Published target: Operating loss near -$2.16 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 7, 2026-15,089,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows to about $210M in FY26 | A primary condition in Maravai LifeSciences Holdings, Inc.'s published investment case. The stated target is ~$210 million. | Intact | Revenue falls below $185 million in FY26 | Revenue: $51.442M FY2026-Q2; GAAP. Published target: ~$210 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 7, 202651,442,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.09 → $-0.10 · observed estimates
$0.23B → $0.22B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-07-25 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-07-26 | $-0.09 | $225,850,940 | 8 / 8 |
| 2026-07-27 | $-0.09 | $225,850,940 | 8 / 8 |
| 2026-07-28 | $-0.09 | $225,850,940 | 8 / 8 |
| 2026-07-29 | $-0.09 | $225,850,940 | 8 / 8 |
| 2026-07-30 | $-0.09 | $225,850,940 | 8 / 8 |
| 2026-07-31 | $-0.09 | $225,850,940 | 8 / 8 |
| 2026-08-01 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-02 | $-0.09 | $225,850,940 | 8 / 8 |
| 2026-08-03 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-04 | $-0.09 | $225,850,940 | 8 / 8 |
| 2026-08-05 | $-0.09 | $225,850,940 | 8 / 8 |
| 2026-08-06 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-07 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-08 | $-0.09 | $224,788,440 | 6 / 8 |
| 2026-08-09 | $-0.09 | $224,788,440 | 6 / 8 |
| 2026-08-10 | $-0.09 | $224,788,440 | 6 / 8 |
| 2026-08-12 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-13 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-14 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-15 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-16 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-17 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-18 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-19 | $-0.09 | $225,904,125 | 5 / 6 |
| 2026-08-20 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-08-21 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-08-22 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-08-23 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-08-24 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-08-25 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-08-26 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-08-27 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-08-28 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-08-29 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-08-30 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-08-31 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-09-01 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-09-02 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-09-03 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-09-04 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-09-05 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-09-06 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-09-07 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-09-08 | $-0.08 | $225,731,392 | 5 / 6 |
| 2026-09-09 | $-0.08 | $225,731,317 | 5 / 6 |
| 2026-09-10 | $-0.09 | $225,420,173 | 5 / 6 |
| 2026-09-11 | $-0.09 | $225,420,173 | 5 / 6 |
| 2026-09-12 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-13 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-14 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-15 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-16 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-17 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-18 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-19 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-20 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-21 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-22 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-23 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-24 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-25 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-26 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-27 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-28 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-29 | $-0.09 | $225,420,173 | 5 / 7 |
| 2026-09-30 | $-0.10 | $224,647,695 | 5 / 7 |
| 2026-10-01 | $-0.10 | $224,647,695 | 5 / 6 |
| 2026-10-02 | $-0.10 | $224,647,695 | 5 / 6 |
| 2026-10-03 | $-0.10 | $224,647,695 | 5 / 6 |
| 2026-10-04 | $-0.10 | $224,647,695 | 5 / 6 |
| 2026-10-05 | $-0.10 | $224,647,695 | 5 / 6 |
| 2026-10-06 | $-0.10 | $224,886,840 | 5 / 6 |
| 2026-10-07 | $-0.10 | $224,886,840 | 5 / 7 |
| 2026-10-08 | $-0.10 | $224,886,840 | 5 / 7 |
| 2026-10-09 | $-0.10 | $224,886,840 | 5 / 7 |
| 2026-10-10 | $-0.10 | $224,886,840 | 5 / 7 |
| 2026-10-11 | $-0.10 | $224,886,840 | 5 / 7 |
| 2026-10-12 | $-0.10 | $224,886,840 | 5 / 7 |
| 2026-10-13 | $-0.10 | $224,886,840 | 5 / 7 |
| 2026-10-14 | $-0.10 | $224,886,840 | 5 / 7 |
| 2026-10-15 | $-0.10 | $224,886,840 | 5 / 7 |
| 2026-10-16 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-17 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-18 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-19 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-20 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-21 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-22 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-23 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-24 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-25 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-26 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-27 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-28 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-29 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-30 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-10-31 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-11-01 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-11-02 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-11-03 | $-0.10 | $224,904,047 | 5 / 7 |
| 2026-11-04 | $-0.10 | $224,904,047 | 5 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 4 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.